US 11,673,968 B2
Anti-BRDU antibodies and methods of use
Ulrich Brinkmann, Weilheim (DE); Guy Georges, Habach (DE); Johannes Auer, Schwaigen (DE); and Wilma Lau, Munich (DE)
Assigned to Hoffmann-La Roche Inc., Little Falls, NJ (US)
Filed by Hoffmann-La Roche Inc., Little Falls, NJ (US)
Filed on Mar. 5, 2019, as Appl. No. 16/293,478.
Application 16/293,478 is a continuation of application No. 15/382,329, filed on Dec. 16, 2016, abandoned.
Application 15/382,329 is a continuation of application No. PCT/EP2015/064322, filed on Jun. 25, 2015.
Claims priority of application No. 14174043 (EP), filed on Jun. 26, 2014.
Prior Publication US 2020/0002437 A1, Jan. 2, 2020
Int. Cl. C07K 16/00 (2006.01); C07K 16/44 (2006.01); C07K 16/28 (2006.01); A61K 47/62 (2017.01); A61K 47/68 (2017.01); A61K 47/54 (2017.01)
CPC C07K 16/44 (2013.01) [A61K 47/549 (2017.08); A61K 47/62 (2017.08); A61K 47/6803 (2017.08); A61K 47/6879 (2017.08); C07K 16/2881 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/55 (2013.01); C07K 2317/622 (2013.01); C07K 2317/624 (2013.01)] 3 Claims
OG exemplary drawing
 
1. A humanized anti-BRDU antibody, wherein the antibody comprises a VH with the amino acid sequence of SEQ ID NO: 09 and a VL with the amino acid sequence of SEQ ID NO: 10.